TABLE 1.
Baseline characteristics of the patients.
| Characteristic | Non-obesity (n = 505) | Obesity (n = 49) | P |
|---|---|---|---|
| Age (years) (%) | |||
| ≤60 | 302 (59.8) | 29 (59.2) | 0.933 |
| >60 | 203 (40.2) | 20 (40.8) | |
| Gender (%) | |||
| Male | 317 (62.8) | 27 (55.1) | 0.291 |
| Female | 188 (37.2) | 22 (44.9) | |
| Smoking history (%) | |||
| Never | 257 (50.9) | 31 (63.3) | 0.098 |
| Current/former | 248 (49.1) | 18 (36.7) | |
| ECOG (%) | |||
| 0 | 76 (15.0) | 15 (30.6) | 0.005 |
| 1–2 | 429 (85.0) | 34 (69.4) | |
| Histology (%) | |||
| Adenocarcinoma | 415 (82.2) | 42 (85.7) | 0.534 |
| Squamous | 90 (17.8) | 7 (14.3) | |
| Stage (%) | |||
| Ⅲ | 29 (5.8) | 1 (2.0) | 0.443 |
| Ⅳ | 474 (94.2) | 48 (98.0) | |
| EGFR mutation (%) | |||
| Positive | 147 (29.1) | 12 (24.5) | 0.776 |
| Negative | 295 (58.4) | 30 (61.2) | |
| Unknown | 63 (12.5) | 7 (14.3) | |
| Number of metastases (%) | |||
| ≤3 | 259 (51.3) | 30 (61.2) | 0.184 |
| >3 | 246 (48.7) | 19 (38.8) | |
| Treatment (%) | |||
| Anlotinib | 318 (63.0) | 36 (73.5) | 0.144 |
| Placebo | 187 (37.0) | 13 (26.5) | |
| Lines of previous chemotherapy (%) | |||
| 1–2 | 281 (55.6) | 19 (38.8) | 0.006 |
| ≥3 | 224 (44.4) | 29 (59.2) | |
| Unknown | 0 (0) | 1 (2.0) | |
| Previous | |||
| Targeted treatment (%) | |||
| Yes | 217 (43.0) | 29 (59.2) | 0.771 |
| No | 288 (57.0) | 20 (40.8) | |
| Radiotherapy history (%) | |||
| Yes | 204 (40.4) | 18 (36.7) | 0.618 |
| No | 301 (59.6) | 31 (63.3) | |
The bold values mean that the p value was considered statistically significant.
Abbreviations: Eastern Cooperative Oncology Group (ECOG); epidermal growth factor receptor (EGFR).